AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33165612
Drug: SPECTRUM investigational
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECTRUM investigational cigarettes (0.4 mg/g)
Trial: 33055441
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of ceramide-containing food (0.8 mg of dihydroceramide) for 12 weeks
Trial: 34674222
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg once daily (q.d.)
Trial: 34674222
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg q.d. plus erythromycin 500 mg three times daily for seven days
Trial: 35428210
Drug: Hypofractionated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated treatment arm (20 × 3 Gy)
Trial: 35428210
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated treatment arm (35 × 2 Gy)
Trial: 35420334
Drug: Aspirin (placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (placebo-controlled trial)
Trial: 34172436
Drug: efpeglenatide 6
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efpeglenatide 6 mg weekly (QW)
Trial: 34172436
Drug: efpeglenatide 16
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efpeglenatide 16 mg monthly (QM)
Trial: 34172436
Drug: efpeglenatide 6
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efpeglenatide 6 mg QW and 16 mg QM
Trial: 34172436
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg daily (QD)
Trial: 35226547
Drug: Intravenous Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Alteplase before Endovascular Thrombectomy
Trial: 34992358
Drug: Nocturnal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal oxygen therapy (NOT) at 3 L/min via nasal cannula
Trial: 34992358
Drug: Placebo (ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ambient air) at 3 L/min via nasal cannula
Trial: 35125385
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion) + DEX (0.5 µg/kg)
Trial: 35125385
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Trial: 35125385
Drug: DEX (0.5
RxNorm normalized name: hydroxypropylbetadex (0.58-0.68 MS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (0.5 µg/kg)
Trial: 32739411
Drug: 1.8 g
RxNorm normalized name: Calciquid, 1.8 g/5 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g phlorizin-rich apple extract (HIGH)
Trial: 32739411
Drug: 1.35 g
RxNorm normalized name: Octinoxate 1.35 g in 30 g TOPICAL CREAM [LBel Supremacie Teint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.35 g phlorizin-rich apple extract (MED)
Trial: 32739411
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g phlorizin-rich apple extract (LOW)
Trial: 32739411
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g phlorizin-rich apple extract (CON)
Trial: 34171389
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose + oral iron bisglycinate (60 mg for 45 days)
Trial: 34171389
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose only
Trial: 34171389
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose + oral iron bisglycinate
Trial: 35922216
Drug: Cinepazide maleate
RxNorm normalized name: cinepazide maleate
DrugBank: Cinepazide (DB12123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinepazide maleate injection
Trial: 39474720
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg/day
Trial: 34462864
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 4 weeks + topical corticosteroids (TCS)
Trial: 34462864
Drug: Dupilumab 100
RxNorm normalized name: DUPILUMAB 100MG/0.67ML INJ,SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 100 or 200 mg every 2 weeks + TCS
Trial: 33228511
Drug: Omacor 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor 2 g/day
Trial: 39075484
Drug: Aspirin continuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin continuation
Trial: 34718493
Drug: Aspirin discontinuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin discontinuation
Trial: 35676012
Drug: Durable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durable polymer drug-eluting stents (DP-DES)
Trial: 34696674
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg/day)
Trial: 33524545
Drug: Neoadjuvant ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant ADT for 6 months starting 4 months before prostate radiation therapy
Trial: 33524545
Drug: Adjuvant ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant ADT for 6 months starting simultaneously with prostate radiation therapy
Trial: 32166681
Drug: 80 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp, 270 mgI/mL
Trial: 32166681
Drug: 100 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp, 270 mgI/mL
Trial: 32166681
Drug: 100 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp, 320 mgI/mL
Trial: 32166681
Drug: 100 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp, 400 mgI/mL
Trial: 32794481
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy (cervical isometrics and targeted muscle stretchings)
Trial: 35266184
Drug: Capacitive resistive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capacitive resistive monopolar radiofrequency (CRMRF) treatment at 448 kHz
Trial: 35266184
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment with the same physiotherapeutic techniques
Trial: 34218053
Drug: Dexamethasone 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1.8 mg daily
Trial: 32975383
Drug: Urinary catheter
RxNorm normalized name: urinary catheter maintenance solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary catheter removal timing in rectal surgery
Trial: 36286741
Drug: Bifiform 2
RxNorm normalized name: CATHETER,URETHRAL 9FR,FILIFORM TIP DILATION BALLOON #G17843
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifiform 2 capsules 2 times a day for 2 weeks, along with mebeverin 200 mg 2 times a day or trimebutin 200 mg 3 times a day for 4 weeks, rifaximin 400 mg 3 times a day or nifuroxazide 400 mg 2 times a day for 1 week, and a drug that normalizes feces consistency (dioctahedral smectite or macrogol 4000)
Trial: 36286741
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received similar therapy without Bifiform
Trial: 36271257
Drug: Intraventricular KCl
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraventricular KCl injection
Trial: 36271257
Drug: Interventricular septal
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventricular septal KCl administration
Trial: 35852527
Drug: Omecamtiv mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil (n = 185), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg for 20 weeks.
Trial: 35852527
Drug: Placebo (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (n = 91), given orally twice daily for 20 weeks.
Trial: 35938324
Drug: Micro‐needle knife
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro‐needle knife therapy
Trial: 35938324
Drug: Betahistine mesilate
RxNorm normalized name: Betahistine mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine mesilate tablets (6 mg, three times a day for 14 days)
Trial: 39334205
Drug: Proton-pump inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitors
Trial: 35561151
Drug: Oral ultramicrosize
RxNorm normalized name: GRISEOFULVIN,ULTRAMICROSIZE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ultramicrosize griseofulvin (Group A)
Trial: 33740751
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection with triamcinolone hexacetonide (40 mg)
Trial: 36356613
Drug: Setmelanotide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setmelanotide (up to 3.0 mg subcutaneous once per day for 14 weeks)
Trial: 33960840
Drug: Original balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original balloon dilator (created with two middle fingers of a #8 powder‐free surgical glove tied to a nondisposable 11 mm trocar and filled with 600 mL of saline)
Trial: 34635391
Drug: CYD‐TDV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD‐TDV vaccine
Trial: 33225989
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (2000 mg daily in the form of two 'Fish Oil, Ultra Omega-3' capsules)
Trial: 33225989
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 identical placebo capsules daily)
Trial: 35996760
Drug: Dementia VR-based
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dementia VR-based training with peer support (3-month e-book modules, VR activities, 1-hour monthly peer support meetings)
Trial: 35996760
Drug: Non-VR control
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-VR control group (3-month e-book modules, 1-hour monthly regular staff meetings)
Trial: 35498786
Drug: Monthly motivational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly motivational interviews on smoking reduction, 8-week nicotine replacement therapy, referral to smoking cessation service
Trial: 33069608
Drug: Feedback-guided exercises
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback-guided exercises using the ReHand tablet application
Trial: 36223848
Drug: tezepelumab plus
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tezepelumab plus subcutaneous cat SCIT
Trial: 32839200
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil + probiotics combination
Trial: 36173066
Drug: Lurasidone 20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20-80 mg/d
Trial: 35643872
Drug: Enriched seafood
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched seafood sticks (50 g/day containing 1010 CFUs of heat-inactivated B. animalis subsp. lactis CECT8145, 370 mg/day omega 3, and 1.7 g/day inulin)
Trial: 35643872
Drug: Enriched seafood
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched seafood sticks (50 g/day)
Trial: 35643872
Drug: Placebo seafood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo seafood sticks (50 g/day)
Trial: 32933355
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to treatment (exact intervention details not specified)
Trial: 33755884
Drug: Upadacitinib 6
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 6 mg BID
Trial: 33755884
Drug: Upadacitinib 6
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 6 mg BID or higher
Trial: 33755884
Drug: Upadacitinib 6
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 6 mg BID and 24 mg BID
Trial: 33755884
Drug: Upadacitinib 12
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 12 mg BID
Trial: 32171316
Drug: PAT‐A© intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAT‐A© intervention (individualised psychological treatment for anxiety)
Trial: 36037303
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in combination with chemoradiation (chemoRT)
Trial: 32759096
Drug: Transannular pericardial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transannular pericardial patch (TAP)
Trial: 32473596
Drug: Antithrombotic agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic agents (especially heparin-based regimens)
Trial: 34195468
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g soluble corn fiber (SCF)
Trial: 34195468
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg calcium
Trial: 34195468
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g SCF plus 600 mg calcium
Trial: 33262113
Drug: Connected pre-habilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Connected pre-habilitation program during neoadjuvant chemotherapy
Trial: 35495881
Drug: Classical theory
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical theory of Traditional Chinese Medicine (TCM)
Trial: 34126996
Drug: Tart Cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart Cherry (TC) 500 mg
Trial: 35910406
Drug: Ultrasound-guided intercostal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intercostal nerve block with 0.25% ropivacaine and 5 mg dexamethasone
Trial: 35910406
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) with fentanyl
Trial: 34593232
Drug: Tributyrin supplementation
RxNorm normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tributyrin supplementation at 1 g/L
Trial: 34593232
Drug: Tributyrin supplementation
RxNorm normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tributyrin supplementation at 2 g/L
Trial: 34593232
Drug: Tributyrin supplementation
RxNorm normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tributyrin supplementation at 1 g/L and 2 g/L
Trial: 36167528
Drug: MERM device-observed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MERM device-observed self-administered therapy
Trial: 36167528
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard in-person directly observed therapy)
Trial: 36240801
Drug: 210 mg
RxNorm normalized name: aspirin 210 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 210 mg etrolizumab induction
Trial: 36240801
Drug: 105 mg
RxNorm normalized name: menthol 105 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg etrolizumab maintenance
Trial: 36240801
Drug: 105 mg
RxNorm normalized name: menthol 105 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg etrolizumab induction
Trial: 34717532
Drug: Dexmedetomidine (1 μg kg‐ 1)
RxNorm normalized name: dexmedetomidine 0.1 MG/ML
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (1 μg kg‐ 1)
Trial: 34717532
Drug: Lidocaine (1.5 mg kg‐ 1)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg kg‐ 1) with additional propofol (0.5 mg kg‐ 1)
Trial: 32174775
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol/remifentanil
Trial: 34281311
Drug: Concentrated growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated growth factors (CGF) associated with implants
Trial: 34281311
Drug: Standard implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implant treatment (Control)
Trial: 35235632
Drug: Taper thread
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper thread on straight-body implants with microthreads (group A)
Trial: 35235632
Drug: Taper thread
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper thread on straight-body implants without microthreads (group B)
Trial: 35235632
Drug: Implants inserted
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants inserted with IT > 50 Ncm
Trial: 32245513
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of xenon and dexmedetomidine
Trial: 34965510
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of Dexamethasone (LoDex arm) with standardized physical activity for 4 weeks
Trial: 34965510
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of Dexamethasone (HiDex arm) with standardized physical activity for 4 weeks
Trial: 33656569
Drug: oral cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral cladribine
Trial: 34795034
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg via HandiHaler daily for 6 months
Trial: 33755976
Drug: Hemoperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoperfusion therapy
Trial: 35177299
Drug: Moderna vaccine
RxNorm normalized name: Moderna COVID-19 Vaccine
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderna vaccine
Trial: 33636147
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine, BBV152
Trial: 36413230
Drug: 8 mg/d
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/d of extended-release morphine
Trial: 36413230
Drug: 16 mg/d
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/d of extended-release morphine
Trial: 36413230
Drug: 24 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg/d of extended-release morphine
Trial: 36413230
Drug: 32 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg/d of extended-release morphine
Trial: 32144641
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) adapted for bipolar disorder
Trial: 34726114
Drug: GLN (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLN (0.3 g kg FFM-1)
Trial: 34137904
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dextroamphetamine
Trial: 32102920
Drug: pCONUS HPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pCONUS HPC device with single antiplatelet therapy (SAPT) using acetylsalicylic acid (ASA)
Trial: 35303938
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapy (CRRT) and CytoSorb for 72 hours
Trial: 33140125
Drug: Selenised yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenised yeast supplementation at 100, 200, and 300 μg Se/day for 6 months
Trial: 33140125
Drug: Selenised yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenised yeast supplementation at doses over 100 μg Se/day for 5 years
Trial: 35437837
Drug: Eliapixant (10-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant (10-800 mg)